Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
431-01-010 / 431-01-010 ISMRM Abstract

Comparative assessment of 3T edited SVS and MRSI for in vivo detection of 2-hydroxyglutarate and cystathionine in gliomas

Primary: Contrast Mechanisms - Spectroscopy
Secondary: Neuro - Tumors
431-01-010 · From Microstructure to Metabolism: Next-Generation MRI for Brain Tumors · Tuesday, 12 May, 8:20 AM–9:56 AM · Roof Terrace
431-01-010 · From Microstructure to Metabolism: Next-Generation MRI for Brain Tumors · Tuesday, 12 May, 8:20 AM–9:56 AM · Roof Terrace
Keywords: Glioma MRSI Single voxel spectroscopy Cystathionine 2-hydroxyglutarate
Accepted
Francesca Ravera 1,2, Capucine Cadin1, Lucia Nichelli1,3, Bertrand Mathon1,3, Ovidiu C Andronesi4, Eva Niess5, Marc Sanson1,3, Franck Bielle1,3, Stéphane Lehéricy1,3, Malgorzata Marjanska6, Francesca Branzoli1
1Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France
2Siemens Healthcare SAS, Courbevoie, France
3Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Paris, France
4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, United States of America
5Medical University of Vienna, Vienna, Austria
6Center for Magnetic Resonance Research, Dept. of Radiology, University of Minnesota, Minneapolis, United States of America
Presenting Author: Francesca Ravera

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896-913. doi:10.1093/neuonc/nou087 [doi]
2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106 [doi]
3. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology. 2016;27(4):599-608. doi:10.1093/annonc/mdw013 [doi]
4. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629. doi:10.1038/nm.2682 [doi]
5. Branzoli F, Di Stefano AL, Capelle L, et al. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol. 2018;20(7):907-916. doi:10.1093/neuonc/nox214 [doi]
6. Branzoli F, Pontoizeau C, Tchara L, et al. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro Oncol. 2019;21(6):765-774. doi:10.1093/neuonc/noz031 [doi]
7. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Sci Transl Med. 2012;4(116). doi:10.1126/scitranslmed.3002693 [doi]
8. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneousin vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266-272. doi:10.1002/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J [doi]
9. Tkák I, Starcuk Z, Choi IY, Gruetter R. In vivo1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med. 1999;41(4):649-656. doi:10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G [doi]
10. Gruetter R, Tkác I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med. 2000;43(2):319-323. doi:10.1002/(SICI)1522-2594(200002)43:2<319::AID-MRM22>3.0.CO;2-1 [doi]
11. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679. doi:10.1002/mrm.1910300604 [doi]
12. Andronesi OC, Loebel F, Bogner W, et al. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research. 2016;22(7):1632-1641. doi:10.1158/1078-0432.CCR-15-0656 [doi]
13. Nichelli L, Cadin C, Lazzari P, et al. Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH -Mutant Glioma. American Journal of Neuroradiology. 2025;46(1):113-120. doi:10.3174/ajnr.A8413 [doi]
14. Andronesi OC, Arrillaga-Romany IC, Ly KI, et al. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018;9(1):1474. doi:10.1038/s41467-018-03905-6 [doi]
15. Zhou M, Zhou Y, Liao H, et al. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018;20(9):1262-1271. doi:10.1093/neuonc/noy022 [doi]
16. Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data. Neuro Oncol. 2018;20(12):1573-1583. doi:10.1093/neuonc/noy113 [doi]
17. Branzoli F, Liserre R, Deelchand DK, et al. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy. Radiology. 2023;308(3). doi:10.1148/radiol.223255 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/431-01-010